These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Nelfinavir-20200327-v3-终版.pdf (151.47 kB)
Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 Cells
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 27.03.2020 and posted on 30.03.2020by Zhijian Xu, Hangping Yao, Jingshan Shen, Nanping Wu, Yechun Xu, Xiangyun Lu, weiliang zhu, Lan-Juan Li
an integrative computational drug discovery approach, we predicted that
nelfinavir is a potential inhibitor of SARS-CoV-2 main protease. Further
docking nelfinavir to 30 potential target proteins of COVID-19, we found
that nelfinavir is most probably a multi-target agent. The half-maximal
effective concentration (EC50) of nelfinavir mesylate against
SARS-CoV-2 was 2.89±0.65 μM while that of remdesivir was 1.00±0.34 μM,
both drugs showed similar dose-response curves. Based on its high potency
against SARS-CoV-2 at cellular level, its higher exposure in lung than in
plasma, its good safe profile and its potential to reduce inflammation,
nelfinavir deserves further exploration for the treatment of COVID-19.